Originally Aired: April 6, 2023
Time: 11:00 am PT, 2:00 pm ET, 20:00 CET
Immune checkpoint inhibition with monoclonal antibodies targeting PD-1 and PD-L1 has revolutionized the care of patients with advanced cancer, with approvals in multiple solid tumor types and pan-tumor indications. However, current pan-tumor biomarkers do not identify most patients who benefit from these therapies. For example, consider the KEYNOTE-158 study of 10 tumor types that led to pan-solid tumor approval of second-line pembrolizumab monotherapy in patients whose tumor mutation burden was high (TMB-H). While a higher objective response rate (ORR) was observed in TMB-H patients vs. TMB-low (TMB-L), numerically, more objective responses were observed in TMB-L patients.
In this Inside Precision Medicine Webinar, our distinguished guest speaker, Dr. Scott Tomlins, described the development, validation, and clinical utility of a new pan-tumor predictive biomarker for immunotherapy benefit: Immunotherapy Response Score™ (IRS). IRS predicts real-world progression-free survival and overall survival in anti-PD-1/PD-L1 monotherapy-treated patients across tumor types and identifies twice as many patients who may benefit from checkpoint inhibitor treatment as TMB.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from: